Cavazzoni Begins Putting Her Mark On FDA Drug Center With New Principal Deputy Position
Executive Summary
Jacqueline Corrigan-Curay brings a broad array of policy experience, from trial design to real-world evidence to supply chain and post-market surveillance, to the CDER principal deputy director role, though US FDA is not yet able to articulate exactly what her promotion will entail.
You may also be interested in...
The Risk-Reward Of US FDA Leadership Running Offices Below Them
CBER’s Celia Witten is the latest senior executive to run an office within the center during a leadership transition, a move that can help achieve specific goals, but also create tension.
US FDA Board Formed To Manage Increasingly Complex Pharmaceutical Supply Chain Oversight
High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, says CDER’s Jacqueline Corrigan-Curay.
US FDA Board Formed To Manage Increasingly Complex Pharmaceutical Supply Chain Oversight
High-level board will bring together information from across FDA drug center and work to increase supply chain transparency, CDER’s Jacqueline Corrigan-Curay, who will chair the group, tells the Pink Sheet.